Research programme: anti-fibrotic agents - PfizerAlternative Names: UK-383,367; UK-421,045
Latest Information Update: 05 Aug 2009
At a glance
- Originator Pfizer
- Class Hydroxamic acids; Oxadiazoles; Sulfonamides
- Mechanism of Action Bone morphogenetic protein receptor type I antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Scars